<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02620579</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00078287</org_study_id>
    <secondary_id>2R01AR055899</secondary_id>
    <nct_id>NCT02620579</nct_id>
  </id_info>
  <brief_title>Biopsychosocial Influence on Shoulder Pain</brief_title>
  <acronym>BISP</acronym>
  <official_title>Biopsychosocial Influence on Shoulder Pain: a Randomized, Pre-clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic shoulder pain is a common, costly, and disabling problem for society. The
      identification of factors predictive of the development of chronic shoulder pain is necessary
      to develop innovative and effective treatments to reduce the societal impact of shoulder
      disorders. In previous work the investigators identified a genetic and psychological subgroup
      that robustly predicted heightened shoulder pain responses in a pre-clinical cohort and poor
      12 month shoulder pain recovery rates in a clinical surgical cohort. In this follow-up study
      the investigator proposes to test how interventions tailored to the high risk subgroup affect
      pain responses in a pre-clinical cohort.

      The optimal theorized match for the identified high-risk subgroup is a combination of
      personalized pharmaceutical and education interventions. This combined personalized
      intervention versus a placebo pharmaceutical and general education intervention group is the
      primary comparison of interest. Also, an evaluation of the individual effect of personalized
      pharmaceutical and educational interventions will be part of the study. Such comparisons will
      provide important information on what the active portion of the combined personalized
      intervention may be.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Potential subjects will be screened and those meeting the high-risk criteria based on COMT
      genotype for high pain sensitivity and pain catastrophizing questionnaire score will be
      eligible for randomization into intervention groups (stratified by sex). Exercise induced
      shoulder injury will serve as the pain generating mechanism on Day 1 and participants will
      receive pharmaceutical and education interventions over Days 1-4, and Days 2-4 respectively.
      Statistical analysis will determine whether the combined personalized intervention group
      experienced shorter shoulder pain duration, lower peak pain intensity, or decreased
      upper-extremity disability and determine which molecular, psychological, and pain sensitivity
      regulation mechanisms are associated with pain relief. A preliminary analysis is planned
      after the first 300 subjects are equally randomized to the 4 intervention groups. The
      comparison of interest for the preliminary analysis is the combined personalized intervention
      group with the placebo and general education group for the primary outcome. Depending on the
      results of this preliminary analysis the randomization pattern may change, with details of
      these changes available in the protocol paper.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brief Pain Inventory (BPI) for pain duration</measure>
    <time_frame>Daily until recovery criterion met, approximately 5-15 days</time_frame>
    <description>The Brief Pain Inventory (BPI) consists of rating pain intensity on an 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst pain intensity imaginable). This measure will be recorded daily and the recovery criterion used for this study will be a BPI rating of current pain 0/10 and worst pain rating of less than 2/10.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disabilities of the Arm, Shoulder, and Hand Questionnaire (DASH)</measure>
    <time_frame>Daily until recovery criterion met, approximately 5-15 days</time_frame>
    <description>The abridged version of the DASH (the QuickDASH) which consists of 11 functional items, with total scores ranging from 0 (not disability) to 100 (complete disability) will be used to assess upper-extremity disability. The primary outcome will be the highest DASH score recorded during the pain intensity recovery period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brief Pain Inventory (BPI) for peak shoulder pain intensity (highest daily pain intensity rating) recorded during recovery.</measure>
    <time_frame>Daily until recovery criterion met, approximately 5-15 days</time_frame>
    <description>The Brief Pain Inventory (BPI) which consists of rating pain intensity on an 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst pain intensity imaginable). Participants will rate their current, best, and worst pain intensity on the BPI. This measure will be recorded daily through study completion, an average of 5 days. The highest pain intensity rating during that time period will be recorded as the Peak Shoulder Pain Intensity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Catastrophizing Scale (PCS)</measure>
    <time_frame>Daily for 5 days</time_frame>
    <description>The PCS is a 13-item instrument which instruction participants to reflect on past painful experiences, and to indicate the degree to which they experienced each of 13 thoughts or feelings when experiencing pain, on 5-point scales with the end points (0) not at all and (4) all the time. The PCS yields a total score and three subscale scores assessing rumination, magnification and helplessness. The PCS total score is computed by summing responses to all 13 items. PCS total scores range from 0 - 52. The PCS subscales are computed by summing the responses to the following items: Rumination: Sum of items 8, 9, 10, 11 Magnification: Sum of items 6, 7, 13 Helplessness: Sum of items 1, 2, 3, 4, 5, 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tampa Scale of Kinesiophobia (TSK-11)</measure>
    <time_frame>Daily for 5 days</time_frame>
    <description>The TSK-11 is a 11-item self report checklist using a 4-point Likert scale that was developed as a measure of fear of movement or (re)injury. The total score ranges between 11 and 44. A higher value on the TSK indicates a high degree of kinesiophobia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fear of Pain Questionnaire (FPQ)</measure>
    <time_frame>Daily for 5 days</time_frame>
    <description>The Fear of Pain Questionnaire (FPQ) is a self-report measure of pain-related fear containing 3 subscales. We will be using a shortened 9 item version in this study. Participants rate their anticipation of fear on a 5-point Likert scale ranging from 1 (not at all) to 5 (extreme). The 3 FPQ subscales are summed to create one total score. Higher scores indicate a greater pain-related fear and the lower scores indicate a lesser degree of fear. The overall scores range from 9 - 45.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suprathreshold heat pain responses</measure>
    <time_frame>Daily for 5 days</time_frame>
    <description>Suprathreshold heat pain response measures will be completed using the Pathway ATS/CHEPS Model (Medoc, Durham NC) unit or the TSA Neurosensory Analyzer (Medoc, Durham NC). The pain responses will be acquired with a VAS response to each stimulus. The VAS will consist of a 10 cm line whose endpoints are designated as 'no pain sensation' and 'the most intense pain sensation imaginable'. Stimuli will be applied to both arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pressure pain threshold</measure>
    <time_frame>Daily for 5 days</time_frame>
    <description>Pressure pain threshold response measures are done using a pressure algometer. A research assistant will apply pressure at 1kg/second through a application tip at the following anatomical locations: deltoid (local) and tibialis anterior (remote). The pressure pain sensitivity will be determined by recording the kg/cm2 when pain is first reported at each location. Trials will be repeated to ensure consistency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conditioned pain modulation</measure>
    <time_frame>Daily for 5 days</time_frame>
    <description>The conditioning stimulus will be cold water applied to the right arm for up to 60 seconds, and the testing stimulus will be pressure applied to the tibialis anterior opposite the side of fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular and inflammatory measures</measure>
    <time_frame>Daily for 5 days</time_frame>
    <description>These measures will capture relevant inflammatory biomarkers. Thus, we plan to perform assays for IL1B, IL6, IL8, and TNFÎ± at baseline, immediately after the exercise-induced injury, and at regular daily intervals. Additional inflammatory or pain regulatory markers may be assessed depending on updates from other ongoing studies.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">448</enrollment>
  <condition>Shoulder Pain</condition>
  <arm_group>
    <arm_group_label>Personalized Pharmaceutical and Education</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will have propranolol (Propranolol LA) 60 mg administered orally and receive the pain processing education modules as the combined intervention for this arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Pharmaceutical, General Education</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group will have the placebo pharmaceutical administered orally and receive general shoulder anatomy education modules as the interventions for this arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Pharmaceutical, Personalized Education</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will have the placebo pharmaceutical administered orally and receive the pain processing education modules as the combined intervention for this arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Personalized Pharmaceutical, General Education</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will have propranolol (Propranolol LA) 60 mg administered orally and receive general shoulder anatomy education modules as the interventions for this arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol LA (60 mg)</intervention_name>
    <description>Long-acting propranolol (Propranolol LA) 60 mg to be administered orally daily for Days 1 (before exercise induced muscle injury) and Days 2-4 following exercise induced muscle injury.</description>
    <arm_group_label>Personalized Pharmaceutical and Education</arm_group_label>
    <arm_group_label>Personalized Pharmaceutical, General Education</arm_group_label>
    <other_name>Personalized Pharmaceutical</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules will be prepared by the University of Florida Investigational Drug Service to be visually indistinguishable from the active medication and delivered orally. Placebo administration will be done in the same fashion as propranolol - administered on Days 1 (before exercise induced muscle injury) and the Days 2-4 after the exercise induced muscle injury.</description>
    <arm_group_label>Placebo Pharmaceutical, General Education</arm_group_label>
    <arm_group_label>Placebo Pharmaceutical, Personalized Education</arm_group_label>
    <other_name>Placebo Pharmaceutical</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Shoulder Anatomy Education</intervention_name>
    <description>Shoulder anatomy education modules will be administered Days 2-4 (after exercised induced muscle injury) following exercise enhance injury with the goal of participant understanding shoulder anatomy and injury while reviewing: a) structure and arthrokinematics of the shoulder joint; b) muscle anatomy of the shoulder with emphasis on the rotator cuff; and c) potential shoulder pain generators from the exercise-induced injury. This education component will be devoid of information related to pain signaling and cognitive restructuring that characterizes Pain Processing Education modules. These education modules will be scripted and structured so they are provided in a standardized manner for all subjects.</description>
    <arm_group_label>Placebo Pharmaceutical, General Education</arm_group_label>
    <arm_group_label>Personalized Pharmaceutical, General Education</arm_group_label>
    <other_name>General Education</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Pain Processing Education</intervention_name>
    <description>Pain processing education modules will be administered Days 2-4 (after exercised induced muscle injury) following exercise enhance injury with the goal of better understanding of pain processing and psycho-education. This information will encourage shoulder activation by: a) reducing the threat of muscle injury; b) encouraging normal use of the shoulder and arm; and c) addressing specific concerns expressed by the subject (e.g. pain with shoulder motion is a sign of re-injury). This education component will be devoid of detailed information on shoulder anatomy, movement, and injury that characterizes the Shoulder Anatomy Education modules. These education modules will be scripted and structured so they are provided in a standardized manner for all subjects.</description>
    <arm_group_label>Personalized Pharmaceutical and Education</arm_group_label>
    <arm_group_label>Placebo Pharmaceutical, Personalized Education</arm_group_label>
    <other_name>Personalized Education</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  English speaking

        Exclusion Criteria:

          -  chronic pain (&gt; 3 months) in any area,

          -  currently experiencing neck or shoulder pain,

          -  previous history of neck or shoulder pain (operationally defined as experiencing neck
             or shoulder pain for longer than 48 hours or seeking medical treatment for neck or
             shoulder pain),

          -  neurological impairment of the in the upper-extremity (determined by loss of
             sensation, muscle weakness, and reflex changes),

          -  regular participation in upper-extremity weight training,

          -  currently or regular use of pain medication, and

          -  previous history of upper-extremity surgery.

        Additional exclusion criteria for propranolol administration are reported history of or
        presence of any of the following cardiovascular conditions:

          -  clinically significant abnormal 12-lead ECG,

          -  sinus bradycardia (resting heart rate below 55 beats per minute),

          -  greater than first degree heart block,

          -  cardiac failure,

          -  coronary artery disease,

          -  uncontrolled hypertension (resting systolic blood pressure above 140 mm Hg), or
             hypotension (resting systolic blood pressure below 90 mm Hg),

          -  Wolff-Parkinson-White syndrome.

        Non-cardiovascular reasons for study exclusion include:

          -  bronchial asthma,

          -  nonallergic bronchospasm,

          -  history of recent major surgery requiring general anesthesia,

          -  diabetes,

          -  pregnancy,

          -  major depression.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Bishop, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Warren H. Greenfield, III, MS</last_name>
    <phone>352-273-8964</phone>
    <email>whgiii@phhp.ufl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Florida Clinical and Translational Science Institute</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Haugh</last_name>
      <phone>352-273-8157</phone>
      <email>jhaugh@ufl.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/28315479</url>
    <description>Abstract for citation and access to paper</description>
  </link>
  <reference>
    <citation>George SZ, Staud R, Borsa PA, Wu SS, Wallace MR, Greenfield WH, Mackie LN, Fillingim RB. Biopsychosocial influence on shoulder pain: Rationale and protocol for a pre-clinical trial. Contemp Clin Trials. 2017 May;56:9-17. doi: 10.1016/j.cct.2017.03.005. Epub 2017 Mar 14.</citation>
    <PMID>28315479</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2015</study_first_submitted>
  <study_first_submitted_qc>November 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2015</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Personalized Pharmaceutical</keyword>
  <keyword>Personalized Education</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shoulder Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

